{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:23:49Z","timestamp":1761744229920,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,11,6]],"date-time":"2015-11-06T00:00:00Z","timestamp":1446768000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia (PT)","doi-asserted-by":"publisher","award":["SFRH\/BD\/51994\/2012"],"award-info":[{"award-number":["SFRH\/BD\/51994\/2012"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s12253-015-9998-4","type":"journal-article","created":{"date-parts":[[2015,11,6]],"date-time":"2015-11-06T07:13:35Z","timestamp":1446794015000},"page":"301-309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["L744,832 and Everolimus Induce Cytotoxic and Cytostatic Effects in Non-Hodgkin Lymphoma Cells"],"prefix":"10.1007","volume":"22","author":[{"given":"Jos\u00e9","family":"Mendes","sequence":"first","affiliation":[]},{"given":"Ana Cristina","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"Raquel","family":"Alves","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Jorge","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Pires","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Ribeiro","sequence":"additional","affiliation":[]},{"given":"Ana Bela","family":"Sarmento-Ribeiro","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2015,11,6]]},"reference":[{"issue":"9844","key":"9998_CR1","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","volume":"380","author":"KR Shankland","year":"2012","unstructured":"Shankland KR, Armitage JO, Hancock BW (2012) Non-Hodgkin lymphoma. Lancet 380(9844):848\u201357","journal-title":"Lancet"},{"key":"9998_CR2","first-page":"233","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"H Stein","year":"2008","unstructured":"Stein H, Warnke RA, Chan WC, Jaffe ES, Chan JKC, Gatter KC, Campo E (2008) Diffuse large B-cell lymphoma, not otherwise specified. In: Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 233\u2013237"},{"issue":"2","key":"9998_CR3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/j.semdp.2011.04.001","volume":"28","author":"C Schneider","year":"2011","unstructured":"Schneider C, Pasqualucci L, Dalla-Favera R (2011) Molecular pathogenesis of diffuse large B-cell lymphoma. Semin Diagn Pathol 28(2):167\u2013177","journal-title":"Semin Diagn Pathol"},{"issue":"15","key":"9998_CR4","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMra0807082","volume":"362","author":"G Lenz","year":"2010","unstructured":"Lenz G, Staudt LM (2010) Aggressive lymphomas. N Engl J Med 362(15):1417\u20131429","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"9998_CR5","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.3816\/CLM.2009.s.017","volume":"9","author":"VP Kenkre","year":"2009","unstructured":"Kenkre VP, Stock W (2009) Burkitt lymphoma\/leukemia: improving prognosis. Clin Lymphoma Myeloma 9(Suppl 3):S231\u20138","journal-title":"Clin Lymphoma Myeloma"},{"issue":"6","key":"9998_CR6","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.semcancer.2009.07.002","volume":"19","author":"GW Bornkamm","year":"2009","unstructured":"Bornkamm GW (2009) Epstein-Barr virus and its role in the pathogenesis of Burkitt\u2019s lymphoma: an unresolved issue. Semin Cancer Biol 19(6):351\u201365","journal-title":"Semin Cancer Biol"},{"key":"9998_CR7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/asheducation-2002.1.241","volume":"2002","author":"JM Vose","year":"2002","unstructured":"Vose JM, Chiu BC, Cheson BD, Dancey J, Wright J (2002) Update on epidemiology and therapeutics for non-Hodgkin\u2019s lymphoma. Hematol Am Soc Hematol Educ Prog 2002:241\u2013262","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"issue":"6","key":"9998_CR8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1470-2045(04)01490-1","volume":"5","author":"BT Hennessy","year":"2004","unstructured":"Hennessy BT, Hanrahan EO, Daly PA (2004) Non-Hodgkin lymphoma: an update. Lancet Oncol 5(6):341\u2013353","journal-title":"Lancet Oncol"},{"issue":"2","key":"9998_CR9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.uct.2007.08.001","volume":"2","author":"L Castagna","year":"2007","unstructured":"Castagna L, Magagnoli M, Demarco M, Santoro A (2007) Lymphomas. Updat Cancer Ther 2(2):101\u2013110","journal-title":"Updat Cancer Ther"},{"issue":"1","key":"9998_CR10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.blre.2008.05.002","volume":"23","author":"AS Michallet","year":"2009","unstructured":"Michallet AS, Coiffier B (2009) Recent developments in the treatment of aggressive non-Hodgkin lymphoma. Blood Rev 23(1):11\u201323","journal-title":"Blood Rev"},{"issue":"11","key":"9998_CR11","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S1470-2045(10)70210-2","volume":"11","author":"N Murawski","year":"2010","unstructured":"Murawski N, Pfreundschuh M (2010) New drugs for aggressive B-cell and T-cell lymphomas. Lancet Oncol 11(11):1074\u201385","journal-title":"Lancet Oncol"},{"issue":"5","key":"9998_CR12","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1634\/stemcells.2005-0519","volume":"24","author":"BW Parcells","year":"2006","unstructured":"Parcells BW, Ikeda AK, Simms-Waldrip T, Moore TB, Sakamoto KM (2006) FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. Stem Cells 24(5):1174\u20131184","journal-title":"Stem Cells"},{"key":"9998_CR13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/asheducation-2006.1.178","volume":"2006","author":"D Small","year":"2006","unstructured":"Small D (2006) FLT3 mutations: biology and treatment. Hematol Am Soc Hematol Educ Prog 2006:178\u2013184","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"key":"9998_CR14","unstructured":"Morschhauser F, Bezombes C, Jardin F (2010) Targeting molecular pathways. Education Program for the 15th Congress of European Hematology Association 4(1):118\u2013123"},{"issue":"6","key":"9998_CR15","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1182\/blood-2004-12-4621","volume":"106","author":"A Hachem","year":"2005","unstructured":"Hachem A, Gartenhaus RB (2005) Oncogenes as molecular targets in lymphoma. Blood 106(6):1911\u20131923","journal-title":"Blood"},{"issue":"48","key":"9998_CR16","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/sj.onc.1209886","volume":"25","author":"JB Easton","year":"2006","unstructured":"Easton JB, Houghton PJ (2006) MTOR and cancer therapy. Oncogene 25(48):6436\u20136446","journal-title":"Oncogene"},{"issue":"2","key":"9998_CR17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.pharmthera.2013.12.004","volume":"142","author":"J Polivka Jr","year":"2014","unstructured":"Polivka J Jr, Janku F (2014) Molecular targets for cancer therapy in the PI3K\/AKT\/mTOR pathway. Pharmacol Ther 142(2):164\u2013175","journal-title":"Pharmacol Ther"},{"key":"9998_CR18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.semcancer.2013.09.001","volume":"23P","author":"CU Niemann","year":"2013","unstructured":"Niemann CU, Wiestner A (2013) B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol 23P:410\u2013421","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"9998_CR19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.bcmd.2015.06.016","volume":"55","author":"K Bojarczuk","year":"2015","unstructured":"Bojarczuk K, Bobrowicz M, Dwojak M, Miazek N, Zapala P, Bunes A, Siernicka M, Rozanska M, Winiarska M (2015) B-cell receptor signaling in the pathogenesis of lymphoid malignancies. Blood Cells Mol Dis 55(3):255\u201365. doi: 10.1016\/j.bcmd.2015.06.016","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"9998_CR20","first-page":"831","volume":"32","author":"CB Costa","year":"2012","unstructured":"Costa CB, Casalta-Lopes J, Andrade C, Moreira D, Oliveira A, Gon\u00e7alves AC, Alves V, Silva T, Dourado M, Nascimento-Costa JM, Sarmento-Ribeiro AB (2012) Farnesyltransferase inhibitors: molecular evidence of therapeutic efficacy in acute lymphoblastic leukemia through cyclin D1 inhibition. Anticancer Res 32(3):831\u2013838","journal-title":"Anticancer Res"},{"issue":"3","key":"9998_CR21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/sj.neo.7900088","volume":"2","author":"SY Song","year":"2000","unstructured":"Song SY, Meszoely IM, Coffey RJ, Pietenpol JA, Leach SD (2000) K-Ras-independent effects of the farnesyl transferase inhibitor L744,832 on cyclin B1\/Cdc2 kinase activity, G2\/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells. Neoplasia 2(3):261\u2013272","journal-title":"Neoplasia"},{"issue":"6","key":"9998_CR22","first-page":"2318","volume":"6","author":"AA Adjei","year":"2000","unstructured":"Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH (2000) Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res 6(6):2318\u20132325","journal-title":"Clin Cancer Res"},{"issue":"5","key":"9998_CR23","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1083\/jcb.110.5.1489","volume":"110","author":"LA Beck","year":"1990","unstructured":"Beck LA, Hosick TJ, Sinensky M (1990) Isoprenylation is required for the processing of the lamin a precursor. J Cell Biol 110(5):1489\u20131499","journal-title":"J Cell Biol"},{"issue":"1","key":"9998_CR24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0014-5793(97)00989-7","volume":"414","author":"F Kilic","year":"1997","unstructured":"Kilic F, Salas-Marco J, Garland J, Sinensky M (1997) Regulation of prelamin A endoprotease activity by prelamin A. FEBS Lett 414(1):65\u201368","journal-title":"FEBS Lett"},{"issue":"18","key":"9998_CR25","first-page":"5656","volume":"63","author":"TB Brunner","year":"2003","unstructured":"Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ (2003) Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res 63(18):5656\u20135668","journal-title":"Cancer Res"},{"issue":"8","key":"9998_CR26","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1634\/theoncologist.10-8-565","volume":"10","author":"NM Appels","year":"2005","unstructured":"Appels NM, Beijnen JH, Schellens JH (2005) Development of farnesyl transferase inhibitors: a review. Oncologist 10(8):565\u2013578","journal-title":"Oncologist"},{"issue":"8","key":"9998_CR27","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/sj.bjc.6602162","volume":"91","author":"S Chan","year":"2004","unstructured":"Chan S (2004) Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91(8):1420\u20131424","journal-title":"Br J Cancer"},{"issue":"2","key":"9998_CR28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.2008.18.9514","volume":"27","author":"BM Wolpin","year":"2009","unstructured":"Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP, Fuchs CS (2009) Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 27(2):193\u2013198","journal-title":"J Clin Oncol"},{"issue":"13","key":"9998_CR29","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1182\/blood-2004-03-1153","volume":"104","author":"P Frost","year":"2004","unstructured":"Frost P, Moatamed F, Hoang B, Shi Y, Gera J, Yan H, Frost F, Gibbons J, Lichtenstein A (2004) In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 104(13):4181\u20134187","journal-title":"Blood"},{"issue":"6980","key":"9998_CR30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nature02369","volume":"428","author":"HG Wendel","year":"2004","unstructured":"Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428(6980):332\u2013337","journal-title":"Nature"},{"issue":"5","key":"9998_CR31","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-09-1314","volume":"16","author":"PJ Houghton","year":"2010","unstructured":"Houghton PJ (2010) Everolimus. Clin Cancer Res 16(5):1368\u20131372","journal-title":"Clin Cancer Res"},{"issue":"3","key":"9998_CR32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","volume":"182","author":"T Scholzen","year":"2000","unstructured":"Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182(3):311\u2013322","journal-title":"J Cell Physiol"},{"issue":"8","key":"9998_CR33","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/cr.2007.64","volume":"17","author":"Q Yang","year":"2007","unstructured":"Yang Q, Guan KL (2007) Expanding mTOR signaling. Cell Res 17(8):666\u2013681","journal-title":"Cell Res"},{"issue":"1","key":"9998_CR34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11523-011-0175-8","volume":"6","author":"KR Kelly","year":"2011","unstructured":"Kelly KR, Rowe JH, Padmanabhan S, Nawrocki ST, Carew JS (2011) Mammalian target of rapamycin as a target in hematological malignancies. Target Oncol 6(1):53\u201361","journal-title":"Target Oncol"},{"issue":"11","key":"9998_CR35","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4161\/cc.4.11.2159","volume":"4","author":"C Recher","year":"2005","unstructured":"Recher C, Dos Santos C, Demur C, Payrastre B (2005) MTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle 4(11):1540\u20131549","journal-title":"Cell Cycle"},{"key":"9998_CR36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2012.06.012","volume":"22","author":"S Sander","year":"2012","unstructured":"Sander S, Calado DP, Srinivasan L, Kochert K, Zhang B, Rosolowski M, Rodig SJ, Holzmann K, Stilgenbauer S, Siebert R, Bullinger L, Rajewsky K (2012) Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 22:167\u2013179","journal-title":"Cancer Cell"}],"container-title":["Pathology &amp; Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-015-9998-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-015-9998-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-015-9998-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T02:39:34Z","timestamp":1559443174000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-015-9998-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,6]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["9998"],"URL":"https:\/\/doi.org\/10.1007\/s12253-015-9998-4","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"type":"print","value":"1219-4956"},{"type":"electronic","value":"1532-2807"}],"subject":[],"published":{"date-parts":[[2015,11,6]]}}}